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Introduction
The Blepharophimosis Ptosis Epicanthus-inversus
Syndrome (BPES, MIM 110100) is a rare genetic dis-
ease mainly characterized by a complex eyelid malfor-
mation. Zlotogora et al. defined 2 forms of BPES: type
I (with premature ovarian failure [POF]) and type II
(without POF) [1]. BPES is most often an autosomal
dominant disease due to mutations in the FOXL2 gene,
which encodes a forkhead transcription factor [2]. In
several mammals (human, mouse and goat) FOXL2 is
detected in the developing eyelids and in fetal and
adult ovaries. This pattern of expression correlates
with the BPES phenotype [2,3,4]. Gonadal expression
of FOXL2 in mammals starts at the moment of ovari-
an determination, and is maintained through adult-
hood. FOXL2 expression seems restricted to the
somatic compartment of the ovary, with granulosa
cells displaying the strongest protein expression
[2,4,5]. Foxl2 is also expressed in the developing pitu-
itary and might participate in its organogenesis [6,7].
This expression persists in the adult pituitary, especial-
ly in gonadotrope and thyrotrope cells [8]. An explo-
ration of Internet resources suggests that FoxL2 is also
expressed in macrophages, blood reticulocytes, hepa-
tocytes, in the colon, in the heart, etc [9]. In addition,
FOXL2 expression was demonstrated in human fibrob-
lasts [10]. Such a wider expression domain of FOXL2
also suggests a role in the development and/or function
of other tissues.
Mouse models
Two Knock-Out (KO) mouse models have been crea-
ted for Foxl2 [11,12]. Homozygous KO animals dis-
play strong perinatal lethality [12]. The survivors are
characterized by a small size, which is probably linked
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to a reduction of plasmatic Insulin-Like Growth Factor
1 (Igf1) level [12]. Moreover, they have severe cranio-
facial abnormalities, a severe eyelid hypoplasia, and
are born with open eyes [12]. 
Female KO mice are sterile [11,12]. Their ovaries
are small, disorganized and primary follicles are not
formed [11,12]. Schmidt et al. (2004) observed a nor-
mal formation of primordial follicles whose granulosa
cells fail to undergo the normal squamous-to-cuboidal
morphological transition. Indeed, they stay 'flat' and do
not proliferate [11]. In turn, Uda et al. (2004)
described an earlier defect since their KO XX mice do
not form correct primordial follicles [12]. Indeed, the
main defect reported is a perturbation of fragmentation
of the ovigerous cords [12]. These differences between
the onset of the follicular formation defects might be
due to differences in the genetic backgrounds of the
two KO models or in the methods used for phenotypic
analysis. Interestingly, germ cells do not seem affected
during the first stages of folliculogenesis [11,12]. Peri-
natally, the number of oocytes is similar between
mutant and wild-type mice but soon a massive follicu-
lar atresia leads to a severe depletion of the follicular
stock and infertility [11,12]. 
The Foxl2-/- granulosa cells acquire Sertoli cell-
specific characteristics, including expression of Sox9,
Amh, as well as other genes of the testicular differenti-
ation program [13]. Interestingly, forced expression of
Foxl2 in XY transgenic mice leads to seminiferous
tubule disorganization and to the development of
ovotestis-like gonads [14]. These observations suggest
an 'anti-testis' action of Foxl2 by repressing the testis
developmental program but also points to an important
role in the ovary throughout female fertile life.
FOXL2 mutations in BPES
To date, more that 100 unique intragenic FOXL2 muta-
tions (i.e. concerning the coding region) have been
identified in 206 unrelated BPES families from differ-
ent ethnic origin (15 and references therein). Detailed
information on most FOXL2 mutations is available in
the FOXL2 Mutation Database (http://medgen.ugent.
be/foxl2). Intragenic mutations explain about 72% of
typical BPES cases [15,16,17,18,19]. Mutations lead-
ing to an expansion of the polyalanine/polyAla tract
(p.Ala224_Ala234dup, 24 Ala residues instead of 14)
account for 31% and the 17-bp duplication
c.843_859dup (p.P287fs) accounts for 13% of all
reported intragenic FOXL2 mutations. Another, less
recurrent, 17-bp duplication c.855_871dup (p.H291fs),
and mutations c.841_857dup (p.A364fs), c.843_865dup
(p.H289fs), c.854delC (p.P285fs), and c.855_871del17
(p.P287fs), are all clustered in the same region, which
suggests a hypermutability of this sequence
(15,17,19). 
The expansion of the polyAla domain (Ala24) is
most often found in type II BPES (i.e. no ovarian dys-
function) [2,16]. An Ala26 protein has been described
in a BPES patient with an important ovarian cyst [20].
We have recently described a homozygous mutation
leading to Ala19 in a consanguineous BPES family
[21]. 
The phenotypic consequences of nonsense muta-
tions depend on their position in the coding region
(Fig. 1). Early truncation before the forkhead
domain, is likely to lead to plain loss-of-function
(and haploinsufficiency would be the cause of BPES,
i.e. p.Q53X) [22,23] (Fig. 1A)). A nonsense mutation
within the forkhead may also lead to the production
of an inactive protein [16,24,25] (Fig. 1B). However,
truncated FOXL2 proteins containing a complete
forkhead domain, but lacking the polyAla, such as
p.F167X, p.G196X or p.S203X (16,25) might com-
pete with the normal protein for DNA binding and
lead to type I BPES (16,17) (Fig. 1C). Protein trun-
cations after the polyAla (i.e. removing the C-termi-
nus) have also been reported (i.e. p.Y274X) [17,26]
and may lead to both types of BPES [17] (Fig. 1D).
Several artificial nonsense mutations have been
shown to lead to the production of N-terminally trun-
cated proteins by re-initiation of translation down-
stream of the premature stop codon. They seem to
aggregate in the nucleus, and display partial mislo-
calisation to the cytoplasm. In addition, they retain 
a fraction of the wild-type protein [23].
The most recurrent mutation of FOXL2
p.Ala224_Ala234dup (FOXL2-Ala24) (Fig. 1D),
leads to intranuclear aggregation and a mislocalization
of the protein as a result of extensive cytoplasmic
aggregation, whereas the normal FOXL2 protein
exclusively localizes in the nucleus in a diffuse man-
ner [27]. Moreover, p.Ala224_Ala234dup seems to
somehow interfere with the availability/activity of 
a co-expressed normal FOXL2 [27]. Accordingly, 
a potential promoter-specific dominant-negative effect
of FOXL2-Ala24 has been reported [28]. However,
FOXL2-Ala24 seems to retain a partial transactivation
capacity on high-affinity promoters, which might
explain why it is most often associated with BPES
without POF [28,29].
The analysis of missense mutations responsible for
BPES indicates that most of them map to the forkhead
domain (Fig. 1E). Recently, we have studied the molec-
ular consequences of 17 naturally-occurring FOXL2
missense mutations [30]. The subcellular localisation
and aggregation pattern of the mutant FOXL2 proteins
was variable and ranged from a wild-type pattern to
extensive nuclear aggregation often concomitant with
cytoplasmic mislocalisation and aggregation. We also
studied the transactivation capacity of these mutants.
Several mutations led to a loss-of-function, while 
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others were suspected to induce a weak dominant neg-
ative effect. Interestingly, two mutations, located out-
side the forkhead domain (p.S217F and p.S217C), gave
rise to a mild BPES phenotype [30]. Using a structural
3D-model of the forkhead domain we have proposed
that most of the mutations affecting the third helix of
the forkhead domain, such as p.R103C, p.H104R or
p.N105S alter DNA-binding while mutations in the
first or second helices (i.e. p.I63T, p.A66V or p.E69L)
might interfere with protein-protein interactions [26].
The variety of intragenic FOXL2 mutations suggests
that its structure, localization and function are sensitive
to seemingly mild alterations of the protein.
Frameshift mutations leading to elongated proteins
induce the synthesis of (mostly) aberrant proteins. The
position of mutation in the open reading frame (ORF)
is expected to be crucial in the generation of a pheno-
type: the closer to the ATG, the more severe the poten-
tial phenotypic impact. Such abnormal proteins might
have altered function and could also be toxic.
Genomic rearrangements, including deletions
involving FOXL2, also cause BPES. They account for
10% of the molecular defects found in BPES families
[15,18]. The extent of the deletions ranges from a partial
or total gene deletion to microdeletions encompassing
FOXL2 and neighbouring genes including ATR, located
5' to FOXL2. Other cytogenetic deletions found in
BPES patients have been described [31 and references
therein].
The occurrence of three translocation breakpoints
located upstream of FOXL2 illustrated that position
effects may also cause BPES. We have previously
reported on nine extragenic deletions in BPES patients
providing further evidence of potential long-range cis-
regulatory elements regulating FOXL2 expression
[10,18]. The rearrangements outside the transcription
unit are estimated to account for 5% of all molecular
defects found in BPES [15,18].
Before closing this section, it is worth noting that
in a four-generation Chinese family with BPES type II
showing linkage to the FOXL2 locus, an insertion
mutation in the 3' UTR of FOXL2 segregated with the
phenotype. However, the functional significance of
this insertion (in an AU rich repeat) on transcript sta-
bility and/or translation needs to be studied [32].
Genotype/phenotype correlations
It seems difficult to predict the type of BPES just from
the genotype. Type I is supposed to arise from null
mutations, while type II BPES is expected to stem
from hypomorphic (partial function) mutations in the
ovary. An early mutation screening suggested that pro-
tein truncation was expected to lead to a type I BPES
(i.e. with POF), whereas mutations leading to elongat-
ed proteins should produce a type II BPES (no ovarian
dysfunction) [16]. However, predictions are almost
impossible for missense mutations in the forkhead
domain, as they lead to either type of BPES. Moreover,
exceptions to the early genotype/phenotype correla-
tions have been found, since the same mutation can
lead to both types within the same family or in differ-
ent families [15,17]. 
Overall, polyAla expansions lead to BPES type II.
However, variable degrees of ovarian dysfunction
have been observed in seven BPES patients with this
mutation [15,19]. For those patients, it is hypothesized
that these mutations may have a mild effect on ovarian
function giving rise to late-onset ovarian failure, and
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Fig. 1 The predicted protein translation of the wild type FOXL2
protein of 376 aminoacids (top). The vertically striped box indi-
cates the forkhead domain, the dark grey small box shows the
polyalanine (polyAla) tract and the diagonally striped boxes repre-
sent novel amino acids due to a frameshift mutation. The protein
numbering is represented on top of the Figure. Different types of
mutated proteins are shown. A-D are predicted truncated proteins:
(A) without forkhead domain, (B) with partial forkhead, (C) with
complete forkhead and without polyalanine (polyAla) tract, (D)
with complete forkhead and polyAla domains. (E) represents
frameshift mutations leading to elongated proteins with complete
forkhead and polyAla domains; (F) polyAla expansions; (G) mis-
sense mutation in the forkhead domain. 
Fig. 2 Spectrum of genetic defects of the FOXL2 gene and region
in our BPES cohort. (1) intragenic mutations 72%; (2) FOXL2
deletions 10%; (3) extragenic deletions 4%; (4) cytogenetic
defects 2%; (5) unknown genetic defects 12%.
permitting affected females to conceive at younger age
[15]. Moreover, a 16-year old female BPES patient
with an Ala26 expansion had an extremely large cor-
pus luteum cyst, displayed ovarian dysfunction and
was proposed to have BPES type I [20]. These cases
emphasize the importance of appropriate clinical fol-
low-up in patients carrying a polyAla expansion for a
correct assessment of ovarian function. More general-
ly they illustrate that predictive molecular testing for
POF is only meaningful if complemented with clinical
observations [15].
For mutations leading to a truncated or extended
protein containing an intact forkhead and polyAla
tract, the genotype cannot be consistently correlated to
either type of BPES [15,17].
In general, for FOXL2 missense mutations in the
forkhead, no genotype-phenotype correlations can be
made with respect to the ovarian phenotype. However,
it is expected that missense mutations in the forkhead
leading to mislocalization and aggregation, and thus
severely impairing transactivation, will lead to a more
severe ovarian phenotype than missense mutations not
significantly affecting protein localization and func-
tion [19]. In addition, two mutations downstream of
the forkhead domain (p.S217F and p.S217C), were
found to lead to a mild BPES phenotype [30].
Although intragenic FOXL2 mutations usually lead
to BPES type I or II without any extra associated
symptoms, in some patients additional atypical fea-
tures have been described, that might result from
potential pleiotropic effects of these mutations (with
very low penetrance) or due to other genetic or envi-
ronmental factors. A ventricular septal heart defect
(VSD) was found in a patient with a polyAla expan-
sion (c.672_701dup; p.A224_A234dup) and one with
a missense mutation in the forkhead domain
(c.205G>A; p.E69K) respectively. A developmental
delay has been reported in patients carrying the muta-
tion c.273C>G (p.Y91X), c.663_692dup
(p.A221_A231) and c.1056delG (p.E352fs). The com-
bination of a complex heart defect and severe develop-
mental delay was described in a sporadic patient with
mutation c.665C>T (p.Q219X) [19]. An association
between BPES and Duane syndrome was found in 
a 1-year old patient with an expansion of the poly-Ala
tract (c.672_701dup; p.A224_A234dup) [33]. In
another family in which mutation c.663_692dup
(p.Ala221_Ala231dup) was found, a 7-year old male
BPES patient was diagnosed with a cleft palate (Pierre
Robin sequence) while his mother only displays typical
BPES. Another patient with the mutation c.305T>C
(p.Ile102Thr) was born with a cleft lip [19].
Growth hormone deficiency, which has previously
been described in two BPES patients without any other
associated symptoms [34,35], was also found in one
patient with the 17-bp duplication c.672_701dup
(p.A224_A234dup) [2], and two sisters with the mis-
sense mutation c.650C>T (p.S217F). In one BPES
patient with mutation (c.500T>A; c.501C>A) (2),
growth retardation was observed. Growth hormone
deficiency may be attributed to pituitary FOXL2
expression [6,8]. However, most BPES patients do not
have a recognizable pituitary phenotype, suggesting
that the pituitary is less sensitive than the developing
eyelids and ovary to FOXL2 dosage.
For the deletions encompassing FOXL2, no reliable
genotype-phenotype correlations could be established
with respect to POF, as the type of BPES could not be
determined in 9 out of 11 patients [18]. In the 2 fami-
lies where assessment of ovarian function was possi-
ble, the FOXL2 deletion was found to lead to BPES
type I. Furthermore, it was not possible to find a cor-
relation between deletion size and developmental
delay [18]. Although it was postulated that mental
retardation in patients with a microdeletion of the
FOXL2 region might be attributed to haploinsufficien-
cy of ATR [31], a consistent correlation could not be
found [18]. For deletions located outside FOXL2, the
BPES type could only be assessed in 2 out of 5 fami-
lies. They apparently displayed BPES type II [18].
Moreover, no developmental delay was observed in
this subset of patients. 
Allelic disorders
Considering that POF is part of the phenotypic spec-
trum of FOXL2 mutations, FOXL2 was assumed to be
a possible candidate gene for non-syndromic POF
[2,36]. However, the results of several studies
demonstrate that mutations in the FOXL2 coding
region are rarely associated with isolated POF
[16,37,38]. However, FOXL2 variants were identified
in two women with POF from New Zealand and
Slovenia (absent in control chromosomes) [39]. 
A novel 30-bp deletion that was predicted to remove
ten of 14 alanines from the polyAla tract
(c.661_690del; g.898_927del; p.A221_A230del) was
identified in a Slovenian woman who had sponta-
neously conceived and delivered two healthy chil-
dren despite primary amenorrhea and hyperg-
onadotrophic hypogonadism [40]. A novel single
nucleotide substitution c.772T A (c.772T>A;
g.1009T A; p.Y258N) was identified in a New
Zealand woman with POF and her unaffected mother.
More recently, the mutation p.G187D was found in a
woman with premature ovarian failure (POF) in
absence of blepharophimosis syndrome (BPES).
While FOXL2 localization was normal, the transacti-
vation capacity of the mutant protein on two reporter
promoters potentially relevant in an ovarian context
promoters proved to be lower than that of normal
FOXL2 [41].
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Regulation of FOXL2 
In order to better understand the pathogenic effect 
of FOXL2 mutations it is important to understand the
normal regulation of the gene and the targets this tran-
scription factor recognizes. FOXL2 is able to up-regu-
late the activity of its own promoter [29] which might
explain why, once activated, FoxL2 expression is
maintained throughout life [4]. FOXL2 has a rich pat-
tern of post-translational modifications (PTM) iso-
forms in human granulosa-like KGN cells and in
murine ovaries [42]. Perturbations of FOXL2 PTM
profile through forced dephosphorylation or acetyla-
tion have revealed that FOXL2 contains multiple
potential acetylations and phosphorylations [42]. This
study has also suggested that the FOXL2 protein
undergoes parallel processive/concerted modifica-
tions, leading to the existence of several 'mature'
forms. 
FOXL2 expression is upregulated under oxidative
and heat stress in KGN cells [43]. Moreover, FOXL2
is also hyperacetylated in response to oxidative stress.
The positive feedback of FOXL2 can be counteracted
by a negative feedback through the NAD-dependent
deacetylase SIRT1 [43]. Moreover, in vitro experi-
ments indicate that the balance between the positive
and negative feedback loops are disturbed by patho-
genic mutations [43]. Beyond this coarse picture, fur-
ther in-depth studies are required to better understand
the subtleties of the regulation of FOXL2.
Targets of FOXL2
Two pituitary Foxl2 targets have been described thus
far, the gonadotropin-releasing hormone receptor
(GnRHR) and the glycoprotein hormone α-subunit 
(α-GSU) [8,44]. The expression of GnRHR is regulat-
ed through a composite regulatory sequence, the
GnRHR activating sequence (GRAS). GRAS contains
partially overlapping binding sites for Smad3, AP-1
and Foxl2 [44]. Thus, Foxl2 seems to play a role in the
regulation of gonadotropin secretion. This is further
supported by the fact that FOXL2 is able to stimulation
α-GSU expression in both a cellular model and in
transgenic mice [8].
The analysis of Wnt4-/-Foxl2-/- KO mice has shown
that Amh is downregulated in the ovotestis-like gonads
of Foxl2 transgenic XY mice [14]. These observations
suggest that FOXL2 represses directly or indirectly the
expression of SOX9 and AMH in XX gonads, avoiding
ectopic activation of the male sexual differentiation
pathway in females. FoxL2 is also known to regulate
aromatase expression in numerous vertebrate species,
such as goat, chicken and fishes [3,45,46,47].
The Steroidogenesis Acute Response (StAR) cat-
alyzes the translocation of the cholesterol from the
outer to the inner mitochondrial membrane, where it
undergoes transformation into pregnenolone and other
steroids. FOXL2 has been shown to repress the tran-
scriptional activity of the StAR promoter. StAR inhi-
bition by FOXL2 is proposed to maintain immature
follicles in a quiescent state [48]. The role of FOXL2
in steroid metabolism has been further shown in a
recent transcriptome study comparing granulosa-like
KGN cells overexpressing or not FOXL2 [49].
FOXL2 was found to upregulate the expression of
other actors of steroid metabolism, such as
PPARGC1A, NR5A2 and CH25H [49]. Other cellular
pathways are perturbed by FOXL2 overexpression in
KGN tumor cells. This is the case of several inflam-
matory chemokine ligands of the CCL and CXCL
families, as well as of the Prostaglandin synthase 2
(PTGS2) [49]. These results are compatible with the
idea that ovulation is an inflammatory-like process
[50]. Massive follicular atresia occurring in Foxl2-/-
ovaries suggested that FoxL2 acted as an anti-apop-
totic agent [11,12]. More recently, FOXL2 was pro-
posed to be pro-apopototic [51]. This rather ambiva-
lent behavior was illustrated by its ability to upregu-
late the expression of several (pro and anti) apoptosis
regulators in KGN cells [49]. This ambivalence is
shared by other forkhead factors and might be cell- or
condition-dependent [52,53].
FOXL2 overexpression in KGN cells induces the
transcriptional activation of genes involved in the
metabolism of reactive oxygen species (ROS) such as
the Manganese mitochondrial Superoxide Dismutase
(MnSOD) [49]. A direct involvement of FOXL2 in
cell stress response has been recently confirmed [43].
FOXL2 is upregulated by oxidative stress. At the pro-
tein level it is hyperacetylated, which correlates with
an increased recruitment to stress-response promot-
ers, as assessed by Chromatin Immunoprecipitation,
and an increased transactivation capacity [43]. The
gene encoding the SIRT1 deacetylase is also a direct
target of FOXL2 [43]. Interestingly, deacetylation of
FOXL2 by SIRT1 enhances the ability of the former
to regulate the SIRT1 promoter [43]. This negative
feedback loop could serve as a molecular brake,
probably helping to return to "normal"" FOXL2
activity after the end of a stress. The issue of the reg-
ulation of the oxidative stress in the ovary is crucial
because ovulation is accompanied by ROS generation
[54].
The increasing number of known FOXL2 targets in
the adult ovary [49] will be essential to reveal more
insights into phenotypic effects of FOXL2 mutations in
the adult ovary. Moreover, understanding the pathogenic
mechanisms of its mutations might eventually lead to
better diagnostic tools, helping differentiate the two
BPES types, and to better therapies. We hope that basic
research around the regulation of FOXL2 and its targets
will eventually lead to uncover therapeutic molecules.
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